A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
Public ClinicalTrials.gov record NCT02108262. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter randomized, double-blind, placebo-controlled, parallel-group, dose-ranging phase 2b study to investigate the hepatic and renal safety and tolerability of multiple dose administration of two dose levels of CSL112 compared with placebo in subjects with acute myocardial infarction (AMI).
Study identification
- NCT ID
- NCT02108262
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 1,267 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2014 (Type not available)
- Primary completion
- Dec 2015 (Actual)
- Completion
- Mar 2016 (Actual)
- Last update posted
- Mar 15, 2021
2014 – 2016
United States locations
- U.S. sites
- 48
- U.S. states
- 27
- U.S. cities
- 46
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site 16101 | Birmingham | Alabama | 35211 | — |
| Study Site 16078 | Huntsville | Alabama | 35801 | — |
| Study Site - 16168 | Concord | California | 94520 | — |
| Study Site 16168 | Concord | California | 94520 | — |
| Study Site 16147 | Sacramento | California | 95819 | — |
| Study Site 16022 | Torrance | California | 90502 | — |
| Study Site 16130 | Littleton | Colorado | 80120 | — |
| Study Site 16170 | Bridgeport | Connecticut | 06606 | — |
| Study Site 16135 | Danbury | Connecticut | 06810 | — |
| Study Site 16148 | Clearwater | Florida | 33756 | — |
| Study Site 16003 | Jacksonville | Florida | 32209 | — |
| Study Site 16144 | Atlanta | Georgia | 30322 | — |
| Study Site 16112 | Boise | Idaho | 83712 | — |
| Study Site 16060 | Evanston | Illinois | 60201 | — |
| Study Site 16179 | Elkhart | Indiana | 46514 | — |
| Study Site 16102 | Indianapolis | Indiana | 46290 | — |
| Study Site 16025 | West Des Moines | Iowa | 50266 | — |
| Study Site 16088 | Lexington | Kentucky | 40504 | — |
| Study Site 16004 | Lexington | Kentucky | 40536 | — |
| Study Site 16016 | Louisville | Kentucky | 40202 | — |
| Study Site 16208 | Alexandria | Louisiana | 71301 | — |
| Study Site 16062 | Auburn | Maine | 04210 | — |
| Study Site 16079 | Bangor | Maine | 04401 | — |
| Study Site 16031 | Baltimore | Maryland | 21215 | — |
| Study Site 16028 | Detroit | Michigan | 48202 | — |
| Study Site 16061 | Petoskey | Michigan | 49770 | — |
| Study Site 16211 | Minneapolis | Minnesota | 55407 | — |
| Study Site 16234 | Saint Paul | Minnesota | 55102 | — |
| Study Site 16063 | Tupelo | Mississippi | 38801 | — |
| Study Site 16033 | Brooklyn | New York | 11215 | — |
| Study Site 16174 | Buffalo | New York | 14215 | — |
| Study Site 16213 | New York | New York | 10029 | — |
| Study Site 16056 | Durham | North Carolina | 27705 | — |
| Study Site 16201 | Elizabeth City | North Carolina | 27909 | — |
| Study Site 16014 | High Point | North Carolina | 27262 | — |
| Study Site 16024 | Winston-Salem | North Carolina | 27157 | — |
| Study Site 16047 | Cincinnati | Ohio | 45219 | — |
| Study Site 16026 | Hershey | Pennsylvania | 17033 | — |
| Study Site 16100 | Lancaster | Pennsylvania | 17604 | — |
| Study Site 16017 | Philadelphia | Pennsylvania | 19104 | — |
| Study Site 16039 | Greenwood | South Carolina | 29646 | — |
| Study Site 16018 | Rapid City | South Dakota | 57701 | — |
| Study Site 16202 | Greeneville | Tennessee | 37745 | — |
| Study Site 16015 | Amarillo | Texas | 79106 | — |
| Study Site 16099 | Dallas | Texas | 75216 | — |
| Study Site 16241 | Wichita Falls | Texas | 76301 | — |
| Study Site 16038 | Richmond | Virginia | 23298 | — |
| Study Site 16166 | Wausau | Wisconsin | 54401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 141 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02108262, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 15, 2021 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02108262 live on ClinicalTrials.gov.